Allergan to Acquire Oculeve Dry Eye Disease Development Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. MSFT
5. NVDA
6. STZ
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Allergan to Acquire Oculeve Dry Eye Disease Development Programs

Allergan (AGN) to Acquire Oculeve for $125M Plus Milestone Payments

July 6, 2015 7:02 AM EDT

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction. Under the terms of the agreement, Allergan will acquire Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve's lead development program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program. Allergan's 2015 earnings-per-share forecast provided on May 11, 2015 is... More